Glyn Stacey, Chief Executive at SSCBio leads a discussion on the current landscape of ‘Cell Therapy Analytics'.

This Commentary piece explores how the production and delivery of NK cells could provide a new option for clinical treatment of illnesses such as myeloid leukaemia, with the potential for scaling approaches to be incorporated into the treatment process.

Oxford Global's Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Advancing The Implementation Of Automation Technologies For Cell Therapy Development' was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market's growth, its priorities, future outlook, and challenges.